Vitamin D and multiple sclerosis: Review of a possible association

Journal of Pharmacy Practice

Volumn 25, Issue 1, 2012, Pages 75-84

  Summerday, Nicole Marie ^a,b   Brown, Sherrill J ^b   Allington, Douglas R ^a,b   Rivey, Michael P ^a,b  

^a Department of Obstetrics Gynecology   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

experimental autoimmune encephalomyelitis (EAE); multiple sclerosis; recommended daily allowance (RDA); vitamin D

Indexed keywords

19 NOR 1,25 DIHYDROXYVITAMIN D2; 7 DEHYDROCHOLESTEROL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE;

CALCIUM ABSORPTION; CORRELATIONAL STUDY; DISEASE COURSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FRUIT JUICE; HUMAN; MILK; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; RADIATION EXPOSURE; RELAPSE; REVIEW; SALMON; SARDINE; TREATMENT DURATION; TREATMENT OUTCOME; TUNA; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 84859554863     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190011421839     Document Type: Review

References (47)

1. Pedersen LB, Nashold FE, Spach KM, et al. 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by inhibiting chemokine synthesis and monocyte trafficking. J Neurosci Res. 2007;85:2480-2490. (Pubitemid 47204762)
2. Pierrot-Deseilligny C. Clinical implications of a possible role of vitamin D in multiple sclerosis. J Neurol. 2009;256:1468-1479.
3. Souberbielle JC, Body JJ, Lappe JM, et al. Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev. 2010;9:709-715.
4. Wallin MT, Page WF, Kurtzke JF. Multiple sclerosis in US veterans of Vietnam era and later military service: race, sex, and geography. Ann Neurol. 2004;55:65-71. (Pubitemid 38067362)
5. Rosati G. The prevalence of multiple sclerosis in the world: an update. Neurol Sci. 2001;22:117-139. (Pubitemid 33771279)
6. Kamen DL, Tangpricha V. Vitamin D and molecular actions on the immune system: modulation of innate and autoimmunity. J Mol Med. 2010;88:441-450.
7. Cross HS. Extrarenal vitamin D hydroxylase expression and activity in normal and malignant cells; modification of expression by epigenetic mechanisms and dietary substances. Nutr Rev. 2007;65:S108-S112.
8. Hollis BW. Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D. J Nutr. 2005;135:317-322. (Pubitemid 40194499)
9. Holick MF. Vitamin D: a millennium perspective. J Cell Biochem. 2003;88:296-307.
10. Raghuwanshi A, Joshi SS, Christakos S. Vitamin D and multiple sclerosis. J Cell Biochem. 2008;105:338-343.
11. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Food and Nutrition Board. Institute of Medicine. Vitamin D. In: Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, D.C: National Academy Press; 1997:250-281.
12. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357:266-281.
13. Calvo MS, Whiting SJ, Barton CN. Vitamin D fortification in the United States and Canada: current status and needs. Am J Clin Nutr. 2004;80:1710s-1716s.
14. Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr. 1998;68:854-858. (Pubitemid 28471068)
15. Holick MF, Biancuzzo RM, Chen TC, et al. Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2008;93:677-681. (Pubitemid 351398538)
16. Davis CD. Vitamin D and cancer: current dilemmas and future research. Am J Clin Nutr. 2008;88:565S-569S.
17. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 2006;52:61-76. (Pubitemid 44466355)
18. Chabas D, Baranzini SE, Mitchell D, et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 2001;294:1731-1735. (Pubitemid 33104847)
19. Kleinschnitz C, Meuth SG, Kieseier BC, et al. Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets. 2007;7:35-63. (Pubitemid 46388881)
20. Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci. 2008;29:558-565.
21. Mahon DB, Wittke A, Weaver V, et al. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem. 2003;89:922-932. (Pubitemid 36927724)
22. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis. 2007;66:1137-1142. (Pubitemid 47309727)
23. Frohman EM, Racke MK, Raine CS. Multiple sclerosis-The plaque and its pathogenesis. N Engl J Med. 2006;354:942-955.
24. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000;270:701-708. (Pubitemid 30444768)
25. Cantorna MT, Mahon DB. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood). 2004;229:1136-1142. (Pubitemid 39602256)
26. Overbergh L, Decallonne B, Valckx D, et al. Identification and immune regulations of 25-hydroxyvitamin D-1 alpha-hydroxylase in murine macrophages. Clin Exp Immunol. 2000;120:139-146. (Pubitemid 30176911)
27. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr. 2008;88:582S-586S.
28. Kennel KA, Drake MT, Hurley DL. Vitamin D deficiency in adults: when to test and how to treat. Mayo Clin Proc. 2010;85:752-758.
29. Bergman C, Gray-Scott D, Chen JJ, et al. What is next for the dietary reference intakes for bone metabolism related nutrients beyond calcium: phosphorus, magnesium, vitamin D, and fluoride? Crit Rev Food Sci Nutr. 2009;49:136-144.
30. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium. Dietary reference intakes for calciumand vitamin D [Internet]. Washington, DC: Institute of Medicine; 2010 Nov [cited 2011 Apr 19]. http://www.iom.edu/Reports/ 2010/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D/Report-Brief.aspx
31. Heaney RP, Davies KM, Chen TC, et al. Human serum 25- hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77:204-210. (Pubitemid 36015393)
32. Leidig-Bruckner G, Roth HJ, Bruckner T, et al. Are commonly recommended dosages for vitamin D supplementation too low? Vitamin D status and effects of supplementation on serum 25-hydroxyvitamin D levels-an observational study during clinical practice conditions. Osteoporos Int. 2011;22:231-240.
33. Hammond SR, de Wytt C, Maxwell IC, et al. The epidemiology of multiple sclerosis in Queensland, Australia. J Neurol Sci. 1987;80:185-204. (Pubitemid 17133667)
34. Beretich BD, Beretich TM. Explaining multiple sclerosis prevalence by ultraviolet exposure: a geospatial analysis. Mult Scler. 2009;15:891-898.
35. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA. 2006;296:2832-2838. (Pubitemid 44969183)
36. Freedman MD, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: a case-control study based on death certificates. Occup Environ Med. 2000;57:418-421. (Pubitemid 30312755)
37. Becklund BR, Severson KS, Vang SV, et al. UV radiation suppresses experimental autoimmune encephalomyelitis independent of vitamin D production. Proc Natl Acad Sci USA. 2010;107:6418-6423.
38. Ozgocmen S, Bulut S, Ilhan N, et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J Bone Miner Metab. 2005;23:309-313. (Pubitemid 40875090)
39. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60-65. (Pubitemid 38082871)
40. Soilu-Hanninen M, Airas L, Mononen I, et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler. 2005;11:266-271. (Pubitemid 40775180)
41. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain. 2009;132:1146-1160.
42. Fleming JO, Hummel AL, Beinlich BR, et al. Vitamin D treatment of relapsing-remitting multiple sclerosis (RRMS): a MRI-based pilot study [abstract]. Neurology. 2000;54:A338.
43. Wingerchuk DM, Lesaux J, Rice GP, et al. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76:1294-1296. (Pubitemid 41208389)
44. Goldberg P, Fleming MC, Picard EH. Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin D. Med Hypotheses. 1986;21:193-200. (Pubitemid 17201931)
45. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology. 2010;74:1852-1859.
46. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol. 2005;175:4119-4126. (Pubitemid 41292076)
47. Vitamin D. Drug Facts and Comparisons. Facts & Comparisons® eAnswers [online]. 2011. Wolters Kluwer Health, Inc. Accessed April 6, 2011.